

**Central lab Services Clinical Trial Lab Services - Company Evaluation Report, 2024**

Market Report | 2025-08-01 | 114 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$2650.00
- Corporate License \$4250.00

**Report description:**

The Central Lab Services Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Central Lab Services. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. MarketsandMarkets 360 Quadrants evaluated over 108 companies, of which the Top 11 Central Lab Services Companies were categorized and recognized as quadrant leaders.

Central Lab Services provide standardized, high-quality laboratory testing for pharmaceutical and biotech companies conducting clinical trials across multiple locations. Instead of relying on various local labs with different standards and equipment, all patient samples from trial sites worldwide are shipped to a single, central laboratory. This facility offers a comprehensive menu of services, including safety testing, complex biomarker analysis, sample management, and harmonized data reporting. This centralized approach ensures consistency, accuracy, and data integrity, which are essential for evaluating a drug's safety and efficacy.

The market is driven by the increasing number, complexity, and globalization of clinical trials. As research focuses more on biologics, personalized medicine, and rare diseases, the need for specialized and esoteric testing grows. Pharmaceutical companies increasingly outsource these functions to central labs to leverage their expertise, advanced technology, and global logistics networks, thereby reducing fixed costs and streamlining trial management. The rigorous demand from regulatory bodies like the FDA and EMA for high-quality, standardized data to support drug approval applications makes central labs an indispensable partner in drug development.

However, the industry faces considerable challenges. Managing the complex global logistics of time- and temperature-sensitive biological samples is a major operational hurdle fraught with risk. Adhering to a patchwork of different international regulations regarding data privacy and sample shipment adds further complexity. The high cost of advanced testing, particularly for genomics and specialized biomarkers, can be substantial. Moreover, the market is highly competitive, putting pressure on pricing and forcing providers to continuously invest in new technologies to maintain a competitive edge.

The 360 Quadrant maps the Central Lab Services companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Central Lab Services quadrant. The top criteria for product footprint evaluation included Phase (Phase I, Phase II, Phase III, Phase IV), Therapeutic Area(Oncology, Infectious Diseases, Neurology, Cardiology, Other Therapeutic Areas), Service Type (Safety Testing, Immunology, Genetic Testing, Coagulation Testing, Pathology Testing, Biomarkers, Companion Diagnostics, Other Tests), Modality (Small Molecules, Biologics (Monoclonal Antibodies, Vaccines, Other Therapeutic Products), Cell & Gene Therapy, Medical Devices & IVD Devices), End User

(Pharmaceutical & Biopharmaceutical Companies, CROs, Medical Device Companies, Other End Users).

#### Key Players:

Major vendors in the Central Lab Services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), and ICON plc (Ireland).

The key strategies major vendors implement in the Central Lab Services market are partnerships, collaborations, product launches, and product enhancements.

#### Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is the undisputed world leader in serving science, offering an unparalleled portfolio of analytical instruments, laboratory equipment, and biopharma services. Through its industry-leading brands, the company provides foundational tools for research, diagnostics, and manufacturing. Strategically, Thermo Fisher acts as an end-to-end partner for the pharmaceutical industry, supporting customers from initial discovery to commercial production. By focusing on high-growth areas like cell and gene therapy, expanding its digital science platforms, and capitalizing on its vast global scale, the company maintains its dominant position in the life sciences ecosystem.

#### IQVIA

IQVIA is a global leader in using data and science to help healthcare clients find better solutions for patients. Formed from the merger of IMS Health and Quintiles, its unique strength lies in combining advanced data analytics with deep clinical research expertise. IQVIA's strategy is to power smarter, faster drug development by leveraging its vast healthcare data and AI-driven CORE platform. By providing data-rich insights for trial design, patient recruitment, and real-world evidence studies, the company solidifies its position as an indispensable partner for the global life sciences industry.

#### ICON plc

ICON plc is a global leader in the contract research organization (CRO) industry, providing comprehensive drug and device development services. Following its transformative acquisition of PRA Health Sciences, the company boasts immense scale and a fully integrated service offering for its pharma and biotech clients. Strategically, ICON focuses on delivering patient-centric and decentralized clinical trials, leveraging technology to improve access and efficiency. By combining its deep therapeutic expertise with a commitment to data-driven solutions and operational excellence, ICON maintains its position as a top-tier partner in advancing global healthcare innovation.

#### Table of Contents:

1 INTRODUCTION	11
1.1 MARKET DEFINITION	11
1.2 STAKEHOLDERS	11
2 EXECUTIVE SUMMARY	12
3 MARKET OVERVIEW	17
3.1 INTRODUCTION	17
3.2 MARKET DYNAMICS	17
3.2.1 DRIVERS	18
3.2.1.1 Increasing number of clinical trials	18
3.2.1.2 Rising investments in research & development	18
3.2.1.3 Growing prevalence of rare diseases	19
3.2.1.4 Favorable government initiatives	20
3.2.2 RESTRAINTS	20
3.2.2.1 High costs associated with clinical trials	20
3.2.2.2 Shortage of skilled professionals	21
3.2.3 OPPORTUNITIES	22
3.2.3.1 Emerging markets worldwide	22
3.2.3.2 Decentralized and virtual clinical trials	22
3.2.4 CHALLENGES	23
3.2.4.1 Regulatory complexities	23

3.2.4.2] Limited patient diversity]24	
3.2.4.3] Cybersecurity and intellectual property concerns]24	
3.3] TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS]25	
3.4] VALUE CHAIN ANALYSIS]26	
3.4.1] RESOURCE ACQUISITION AND PREPARATION]26	
3.4.2] CLINICAL TRIAL EXECUTION]26	
3.4.3] DATA REPORTING AND RESULT SUBMISSION]26	
3.4.4] PROMOTION AND REGULATORY FILING]26	
3.5] ECOSYSTEM ANALYSIS]27	
3.6] TECHNOLOGY ANALYSIS]28	
3.6.1] KEY TECHNOLOGIES]29	
3.6.1.1] Enzyme-linked immunosorbent assay]29	
3.6.2] ADJACENT TECHNOLOGIES]29	
3.6.2.1] Next-generation sequencing]29	
3.7] KEY CONFERENCES AND EVENTS, 2025-2026]30	
?]	
3.8] PORTER'S FIVE FORCES ANALYSIS]31	
3.8.1] THREAT OF NEW ENTRANTS]32	
3.8.2] THREAT OF SUBSTITUTES]32	
3.8.3] BARGAINING POWER OF SUPPLIERS]32	
3.8.4] BARGAINING POWER OF BUYERS]32	
3.8.5] INTENSITY OF COMPETITIVE RIVALRY]33	
3.9] IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET]33	
3.9.1] INTRODUCTION]33	
3.9.2] MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES]33	
3.9.3] AI USE CASES]34	
3.9.4] FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM]35	
4] COMPETITIVE LANDSCAPE]36	
4.1] OVERVIEW]36	
4.2] KEY PLAYER STRATEGIES/RIGHT TO WIN]36	
4.2.1] OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET]36	
4.3] REVENUE ANALYSIS, 2020?2024]38	
4.4] MARKET SHARE ANALYSIS, 2024]39	
4.5] COMPANY VALUATION AND FINANCIAL METRICS]41	
4.6] BRAND/PRODUCT COMPARISON]42	
4.7] COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024]43	
4.7.1] STARS]43	
4.7.2] EMERGING LEADERS]43	
4.7.3] PERVERSIVE PLAYERS]43	
4.7.4] PARTICIPANTS]43	
4.7.5] COMPANY FOOTPRINT: KEY PLAYERS, 2024]45	
4.7.5.1] Company footprint]45	
4.7.5.2] Region footprint]46	
4.7.5.3] Product type footprint]47	
4.7.5.4] Therapeutic area footprint]48	
4.7.5.5] Phase footprint]49	
4.8] COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024]50	

4.8.1 PROGRESSIVE COMPANIES	50
4.8.2 RESPONSIVE COMPANIES	50
4.8.3 DYNAMIC COMPANIES	50
4.8.4 STARTING BLOCKS	50
4.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	52
4.8.5.1 Detailed list of key startups/SMEs	52
4.8.5.2 Competitive benchmarking of key startups/SMEs	53
?	
4.9 COMPETITIVE SCENARIO	54
4.9.1 PRODUCT LAUNCHES	54
4.9.2 DEALS	55
4.9.3 EXPANSIONS	56
4.9.4 OTHER DEVELOPMENTS	56
5 COMPANY PROFILES	57
5.1 KEY PLAYERS	57
5.1.1 THERMO FISHER SCIENTIFIC INC.	57
5.1.1.1 Business overview	57
5.1.1.2 Products/Services offered	58
5.1.1.3 Recent developments	59
5.1.1.3.1 Product launches	59
5.1.1.3.2 Deals	59
5.1.1.3.3 Expansions	60
5.1.1.4 MnM view	60
5.1.1.4.1 Key strengths	60
5.1.1.4.2 Strategic choices	60
5.1.1.4.3 Weaknesses and competitive threats	60
5.1.2 IQVIA	61
5.1.2.1 Business overview	61
5.1.2.2 Products/Services offered	62
5.1.2.3 Recent developments	63
5.1.2.3.1 Product launches	63
5.1.2.3.2 Deals	64
5.1.2.4 MnM view	64
5.1.2.4.1 Right to win	64
5.1.2.4.2 Strategic choices	64
5.1.2.4.3 Weaknesses and competitive threats	64
5.1.3 ICON PLC	65
5.1.3.1 Business overview	65
5.1.3.2 Products/Services offered	66
5.1.3.3 Recent developments	66
5.1.3.3.1 Product launches	66
5.1.3.3.2 Deals	67
5.1.3.4 MnM view	67
5.1.3.4.1 Right to win	67
5.1.3.4.2 Strategic choices	67
5.1.3.4.3 Weaknesses and competitive threats	67
5.1.4 CHARLES RIVER LABORATORIES	68

5.1.4.1	Business overview	68
5.1.4.2	Products/Services offered	69
5.1.4.3	Recent developments	70
5.1.4.3.1	Deals	70
5.1.4.3.2	Expansions	71
5.1.4.4	MnM view	71
5.1.4.4.1	Right to win	71
5.1.4.4.2	Strategic choices	71
5.1.4.4.3	Weaknesses and competitive threats	71
5.1.5	LABCORP	72
5.1.5.1	Business overview	72
5.1.5.2	Products/Services offered	73
5.1.5.3	Recent developments	74
5.1.5.3.1	Product launches	74
5.1.5.3.2	Deals	74
5.1.5.3.3	Expansions	75
5.1.5.3.4	Other developments	75
5.1.5.4	MnM view	76
5.1.5.4.1	Key strengths	76
5.1.5.4.2	Strategic choices	76
5.1.5.4.3	Weaknesses and competitive threats	76
5.1.6	QUEST DIAGNOSTICS	77
5.1.6.1	Business overview	77
5.1.6.2	Products/Services offered	78
5.1.6.3	Recent developments	78
5.1.6.3.1	Deals	78
5.1.7	MEDPACE	80
5.1.7.1	Business overview	80
5.1.7.2	Products/Services offered	81
5.1.7.3	Recent developments	81
5.1.7.3.1	Expansions	81
5.1.8	FRONTAGE LABS	82
5.1.8.1	Business overview	82
5.1.8.2	Products/Services offered	84
5.1.9	SGS SOCIETE GENERALE DE SURVEILLANCE SA	85
5.1.9.1	Business overview	85
5.1.9.2	Products/Services offered	86
5.1.9.3	Recent developments	87
5.1.9.3.1	Deals	87
5.1.10	EUROFINS SCIENTIFIC	88
5.1.10.1	Business overview	88
5.1.10.2	Products/Services offered	89
5.1.10.3	Recent developments	90
5.1.10.3.1	Deals	90
5.1.11	REPROCELL INC.	91
5.1.11.1	Business overview	91
5.1.11.2	Products/Services offered	91

5.1.11.3 Recent developments	92
5.1.11.3.1 Deals	92
5.1.12 ACM GLOBAL LABORATORIES	93
5.1.12.1 Business overview	93
5.1.12.2 Products/Services offered	93
5.1.12.3 Recent developments	93
5.1.12.3.1 Deals	93
5.2 OTHER PLAYERS	94
5.2.1 WORLDWIDE CLINICAL TRIALS	94
5.2.2 VERSITI	95
5.2.3 CTI CLINICAL TRIAL & CONSULTING	96
5.2.4 CLARITY LABORATORIES, INC	97
5.2.5 NOVOTECH	98
5.2.6 ARUP LABORATORIES	99
5.2.7 PRECISION MEDICINE GROUP	100
5.2.8 BIOAGILYTIX LABS	101
5.2.9 CERBA HEALTHCARE	102
5.2.10 ALMAC GROUP	103
5.2.11 MLM MEDICAL LABS	104
5.2.12 SALVUS BIORESEARCH SOLUTIONS LLP	105
5.2.13 UNILABS	106
6 APPENDIX	107
6.1 RESEARCH METHODOLOGY	107
6.1.1 RESEARCH DATA	107
6.1.1.1 Secondary data	107
6.1.1.2 Primary data	108
6.1.2 RESEARCH ASSUMPTIONS	110
6.1.3 RESEARCH LIMITATIONS	110
6.1.4 RISK ASSESSMENT	111
6.2 COMPANY EVALUATION MATRIX: METHODOLOGY	111
6.3 AUTHOR DETAILS	114

**Central lab Services Clinical Trial Lab Services - Company Evaluation Report, 2024**

Market Report | 2025-08-01 | 114 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$2650.00
	Corporate License	\$4250.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-19"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com